Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis

Clinical Infectious Diseases

Volumn 63, Issue 8, 2016, Pages 1094-1104

  Low, Andrea J ^a,b   Mburu, Gitau ^c,d   Welton, Nicky J ^a   May, Margaret T ^a   Davies, Charlotte F ^a   French, Clare ^a   Turner, Katy M ^a   Looker, Katharine J ^a   Christensen, Hannah ^a   McLean, Susie ^c   Rhodes, Tim ^e   Platt, Lucy ^e   Hickman, Matthew ^a   Guise, Andy ^f   Vickerman, Peter ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Columbia University ^*  (United States)

^c International HIV AIDS Alliance   (United Kingdom)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral treatment (ART); HIV; Medication assisted therapy for opioid dependence (MAT); People who inject drugs (PWID); Systematic review

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; METHADONE;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; EUROPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDONESIA; INTRAVENOUS DRUG ABUSE; META ANALYSIS; MORTALITY; NORTH AMERICA; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; VIRUS INHIBITION; COMPLICATION; DRUG DEPENDENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MEDICATION COMPLIANCE; ODDS RATIO; PUBLISHING; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BUPRENORPHINE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; METHADONE; ODDS RATIO; OPIATE SUBSTITUTION TREATMENT; PUBLICATION BIAS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84990911218     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw416     Document Type: Article

References (38)

1. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-28.
2. Petersen Z, Myers B, van Hout MC, Pluddemann A, Parry C. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. Harm Reduct J 2013; 10:13.
3. Joint United Nations Programme on HIV/AIDS. The gap report 2014: people who inject drugs. Available at: http://www.unaids.org/en/resources/documents/2014/ Peoplewhoinjectdrugs.pdf. Accessed 20 March 2015.
4. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004; 18:2295-303.
5. Oprea C, Ceausu E, Ruta S. Ongoing outbreak of multiple blood-borne infections in injecting drug users in Romania. Public Health 2013; 127:1048-50.
6. Okal J, Geibel S, Muraguri N, et al. Estimates of the size of key populations at risk for HIV infection: men who have sex with men, female sex workers and injecting drug users in Nairobi, Kenya. Sex Transm Infect 2013; 89:366-71.
7. Reid SR. Injection drug use, unsafe medical injections, and HIV in Africa: a systematic review. Harm Reduct J 2009; 6:24.
8. Hatzakis A, Sypsa V, Paraskevis D, et al. Design and baseline findings of a largescale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction 2015; 110:1453-67.
9. Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone-Indiana, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:443-4.
10. Joint United Nations Programme on HIV/AIDS. Fast track: ending the AIDS epidemic by 2030. Available at: http://www.unaids.org/sites/default/files/ media-asset/JC2686-WAD2014report-en.pdf. Accessed 12 November 2015.
11. World Bank. The global HIV epidemics among people who inject drugs. Available at: http://www.worldbank.org/content/dam/Worldbank/document/GlobalHIV EpidemicsAmongPeopleWhoInjectDrugs.pdf. Accessed 2 February 2015.
12. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14:731-47.
13. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy 2007; 18:255-61.
14. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV infected injection drug users. AIDS 2001; 15:1707-15.
15. Kapadia F, Vlahov D, Wu Y, et al. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse 2008; 34:161-70.
16. Krusi A, Milloy MJ, Kerr T, et al. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther 2010; 15:789-96.
17. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
18. Barnighausen T. The HIV treatment cascade and antiretroviral impact in different populations. Curr Opin HIV AIDS 2015; 10:391-4.
19. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997; 315:635-40.
20. Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale, NJ: Erlbaum, 1988.
21. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000; 19:3127-31.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
23. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:// www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed 11 July 2015.
24. Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 2013; 91:102-23.
25. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001; 91:774-80.
26. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010; 341:c3172.
27. Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007; 102:1954-9.
28. Nosyk B, Min JE, Evans E, et al. The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among HIV-positive people who inject drugs. Clin Infect Dis 2015; 61:1157-65.
29. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquir Immune Defic Syndr 1999; 21:114-9.
30. Chakrapani V, Velayudham J, Shunmugam M, Newman PA, Dubrow R. Barriers to antiretroviral treatment access for injecting drug users living with HIV in Chennai, South India. AIDS Care 2014; 26:835-41.
31. Westergaard RP, Ambrose BK, Mehta SH, Kirk GD. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc 2012; 15:10.
32. Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr 2002; 31:S149-53.
33. Nosyk B, Min JE, Colley G, et al. The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS 2015; 29:965-73.
34. Degenhardt L, Mathers BM, Wirtz AL, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. Int J Drug Policy 2014; 25:53-60.
35. United Nations Office on Drugs and Crime.World drug report 2014. Available at: http://www.unodc.org/documents/wdr2014/World-Drug-Report-2014-web.pdf. Accessed 16 June 2015.
36. Strathdee SA, Beyrer C. Threading the needle-how to stop the HIV outbreak in rural Indiana. N Engl J Med 2015; 373:397-9.
37. US President's Emergency Plan for AIDS Relief. Comprehensive HIV prevention for people who inject drugs, revised guidance. Available at: www.pepfar.gov/ documents/organization/144970.pdf. Accessed 10 June 2015.
38. Strathdee SA, Shoptaw S, Dyer TP, Quan VM, Aramrattana A; Substance Use Scientific Committee of the HIVPTN. Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention. Curr Opin HIV AIDS 2012; 7:320-5.